rilzabrutinib + Glucocorticoids
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Immunoglobulin G4 Related Disease
Conditions
Immunoglobulin G4 Related Disease
Trial Timeline
Aug 22, 2020 → Oct 15, 2024
NCT ID
NCT04520451About rilzabrutinib + Glucocorticoids
rilzabrutinib + Glucocorticoids is a phase 2 stage product being developed by Sanofi for Immunoglobulin G4 Related Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04520451. Target conditions include Immunoglobulin G4 Related Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04520451 | Phase 2 | Completed |
Competing Products
11 competing products in Immunoglobulin G4 Related Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-383 (Etentamig) | AbbVie | Phase 1/2 | 41 |
| zigakibart | Novartis | Phase 2 | 52 |
| iptacopan | Novartis | Phase 3 | 77 |
| CCX168 | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Rilzabrutinib + Placebo + Glucocorticoid | Sanofi | Phase 3 | 76 |
| Felzartamab | Biogen | Phase 2 | 49 |
| Felzartamab + Placebo | Biogen | Phase 3 | 74 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| sparsentan + irbesartan + Dapagliflozin | Travere Therapeutics | Phase 3 | 72 |